✦ LIBER ✦

Decreased hearing after combined modality therapy for head and neck cancer

✍ Scribed by Susan E. Pearson; Abby C. Meyer; George L. Adams; Frank G. Ondrey

Book ID: 116213822
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 185 KB
Volume: 27
Category: Article
ISSN: 1532-818X
DOI: 10.1016/j.amjoto.2005.07.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined modality therapy for advanced h

Combined modality therapy for advanced head and neck cancer

✍ Arthur Weaver; John J.K. Loh; Henry Vandenberg; William Powers; Susan Fleming; R 📂 Article 📅 1980 🏛 Elsevier Science 🌐 English ⚖ 432 KB

Hypothyroidism complicating combined mod

Hypothyroidism complicating combined modality therapy for head and neck malignancy

✍ D.Ian Hodson; R. Talbot-Jones; K. Malaker 📂 Article 📅 1981 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Combined modality treatment of advanced

Combined modality treatment of advanced head and neck cancer

✍ R.R. Weichselbaum; T.J. Ervin; M. Posner; D. Miller 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 241 KB

Current issues in combined modality ther

Current issues in combined modality therapy in locally advanced head and neck cancer

✍ Anthony J. Cmelak 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 175 KB

Induction Therapy in the Modern Era of C

Induction Therapy in the Modern Era of Combined-Modality Therapy for Locally Advanced Head and Neck Cancer

✍ Marshall Posner; Jan B. Vermorken 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 109 KB

Neck dissection in the combined-modality

Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer

✍ Athanassios Argiris; Kerstin M. Stenson; Bruce E. Brockstein; Bharat B. Mittal; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 2 views

## Abstract ## Purpose. The purpose of this study was to evaluate the role of neck lymph node (ND) in the combined dissection modality therapy for locoregionally advanced head and neck. ## Methods. We identified patients with N2–N3 head and neck cancers who were enrolled in three consecutive mul